Three-year changes of cortical 18F-FDG in amnestic vs. non-amnestic sporadic early-onset Alzheimer’s disease

Vanhoutte, Matthieu; Semah, Franck; Leclerc, Xavier; Sillaire, Adeline Rollin; Jaillard, Assia; Kuchcinski, Grégory; Delbeuck, Xavier; Fahmi, Rachid; Pasquier, Florence; Lopes, Renaud

doi:10.1007/s00259-019-04519-w

Cited by 5 publications

(8 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One specificity of EOAD is the higher frequency of non-amnestic variants when compared to LOAD (Palasí et al, 2015 ). Amnestic and non-amnestic forms have different origins and evolution on the cerebral degeneration (Ossenkoppele et al, 2015 ; Xia et al, 2017 ; Phillips et al, 2018 ; Riedel et al, 2018 ; Vanhoutte et al, 2020 ). We investigated PAD score as a marker of phenotypic heterogeneity in EOAD for diagnosis.…”

Section: Discussionmentioning

confidence: 99%

“…Despite the growing interest to better understand the mechanisms underlying phenotypic heterogeneity in EOAD using MRI (Mendez, 2012 ; Falgàs et al, 2020a ; Vanhoutte et al, 2020 ), there is a potential bridge between these group-level studies and the clinical care of individual AD patients. The aim of this study was to investigate the PAD as a marker of phenotypic heterogeneity in EOAD for diagnostic and follow-up purposes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Longitudinal Analysis of Brain-Predicted Age in Amnestic and Non-amnestic Sporadic Early-Onset Alzheimer's Disease

Gautherot

Kuchcinski

Bordier

et al. 2021

Front. Aging Neurosci.

Self Cite

View full text Add to dashboard Cite

Objective: Predicted age difference (PAD) is a score computed by subtracting chronological age from “brain” age, which is estimated using neuroimaging data. The goal of this study was to evaluate the PAD as a marker of phenotypic heterogeneity and severity among early-onset Alzheimer's disease (EOAD) patients.Methods: We first used 3D T1-weighted (3D-T1) magnetic resonance images (MRI) of 3,227 healthy subjects aged between 18 and 85 years to train, optimize, and evaluate the brain age model. A total of 123 participants who met the criteria for early-onset (<65 years) sporadic form of probable Alzheimer's disease (AD) and presented with two distinctive clinical presentations [an amnestic form (n = 74) and a non-amnestic form (n = 49)] were included at baseline and followed-up for a maximum period of 4 years. All the participants underwent a work-up at baseline and every year during the follow-up period, which included clinical examination, neuropsychological testing and genotyping, and structural MRI. In addition, cerebrospinal fluid biomarker assay was recorded at baseline. PAD score was calculated by applying brain age model to 3D-T1 images of the EOAD patients and healthy controls, who were matched based on age and sex. At baseline, between-group differences for neuropsychological and PAD scores were assessed using linear models. Regarding longitudinal analysis of neuropsychological and PAD scores, differences between amnestic and non-amnestic participants were analyzed using linear mixed-effects modeling.Results: PAD score was significantly higher for non-amnestic patients (2.35 ± 0.91) when compared to amnestic patients (2.09 ± 0.74) and controls (0.00 ± 1). Moreover, PAD score was linearly correlated with the Mini-Mental State Examination (MMSE) and the Clinical Dementia Rating Sum of Boxes (CDR-SB), for both amnestic and non-amnestic sporadic forms. Longitudinal analyses showed that the gradual development of the disease in patients was accompanied by a significant increase in PAD score over time, for both amnestic and non-amnestic patients.Conclusion: PAD score was able to separate amnestic and non-amnestic sporadic forms. Regardless of the clinical presentation, as PAD score was a way of quantifying an early brain age acceleration, it was an appropriate method to detect the development of AD and follow the evolution of the disease as a marker of severity as MMSE and CDR-SB.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Longitudinal Analysis of Brain-Predicted Age in Amnestic and Non-amnestic Sporadic Early-Onset Alzheimer's Disease

Gautherot

Kuchcinski

Bordier

et al. 2021

Front. Aging Neurosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Atypical forms differ from amnestic Alzheimer disease not only because they first hit different sites of the brain but also because they show different spatial and temporal patterns in the progression of brain damage [18]. Along this line, Vanhoutte et al [19] suggested that the decline of glucose metabolism in amnestic forms progresses along an anterior-to-posterior axis, whereas in non-amnestic forms, it progresses along a posterior-to-anterior axis. Recently, a 1-year follow-up study of Alzheimer's disease variants combining MRI, tau, and amyloid PET [17] found a similar cortical pattern of Aβ deposition that did not change over time.…”

Section: Translation To the Clinical Practicementioning

confidence: 99%

A future for PET imaging in Alzheimer’s disease

Kas

Migliaccio

Tavitian

2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…One specificity of EOAD is the higher frequency of non-amnestic variants when compared to LOAD (Palasí et al, 2015). Amnestic and non-amnestic forms have different origins and evolution on the cerebral degeneration (Ossenkoppele et al, 2015;Xia et al, 2017;Phillips et al, 2018;Riedel et al, 2018;Vanhoutte et al, 2020). We investigated PAD score as a marker of phenotypic heterogeneity in EOAD for diagnosis.…”

Section: Discussionmentioning

confidence: 99%

“…Despite the growing interest to better understand the mechanisms underlying phenotypic heterogeneity in EOAD using MRI (Mendez, 2012;Falgàs et al, 2020a;Vanhoutte et al, 2020), there is a potential bridge between these group-level studies and the clinical care of individual AD patients. The aim of this study was to investigate the PAD as a marker of phenotypic heterogeneity in EOAD for diagnostic and follow-up purposes.…”

Section: Introductionmentioning

confidence: 99%

Data_Sheet_2.csv

View full text Add to dashboard Cite

Three-year changes of cortical 18F-FDG in amnestic vs. non-amnestic sporadic early-onset Alzheimer’s disease

Cited by 5 publications

References 59 publications

Longitudinal Analysis of Brain-Predicted Age in Amnestic and Non-amnestic Sporadic Early-Onset Alzheimer's Disease

Longitudinal Analysis of Brain-Predicted Age in Amnestic and Non-amnestic Sporadic Early-Onset Alzheimer's Disease

A future for PET imaging in Alzheimer’s disease

Data_Sheet_2.csv

Contact Info

Product

Resources

About